These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 12740917)

  • 1. Differential prognostic impact of the cyclins E and B in premenopausal and postmenopausal women with lymph node-negative breast cancer.
    Rudolph P; Kühling H; Alm P; Fernö M; Baldetorp B; Olsson H; Parwaresch R
    Int J Cancer; 2003 Jul; 105(5):674-80. PubMed ID: 12740917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cyclin-E is a strong predictor of endocrine therapy failure in human breast cancer.
    Span PN; Tjan-Heijnen VC; Manders P; Beex LV; Sweep CG
    Oncogene; 2003 Jul; 22(31):4898-904. PubMed ID: 12894232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of cyclins E, A, and B, and prognosis in lymph node-negative breast cancer.
    Kühling H; Alm P; Olsson H; Fernö M; Baldetorp B; Parwaresch R; Rudolph P
    J Pathol; 2003 Apr; 199(4):424-31. PubMed ID: 12635132
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance.
    Brennan DJ; Jirstrom K; Kronblad A; Millikan RC; Landberg G; Duffy MJ; Rydén L; Gallagher WM; O'Brien SL
    Clin Cancer Res; 2006 Nov; 12(21):6421-31. PubMed ID: 17085655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic significance of bcl-2 expression in stage III breast cancer patients who had received doxorubicin and cyclophosphamide followed by paclitaxel as adjuvant chemotherapy.
    Lee KH; Im SA; Oh DY; Lee SH; Chie EK; Han W; Kim DW; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
    BMC Cancer; 2007 Apr; 7():63. PubMed ID: 17430582
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cyclin E confers a prognostic value in premenopausal breast cancer patients with tumours exhibiting an infiltrative growth pattern.
    Berglund P; Stighall M; Jirström K; Rydén L; Fernö M; Nordenskjöld B; Landberg G
    J Clin Pathol; 2008 Feb; 61(2):184-91. PubMed ID: 17483245
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors in node negative premenopausal women treated with breast conserving therapy without adjuvant systemic therapy.
    Budrukkar AN; Sarin R; Chinoy RF; Badwe R; Shrivastava SK; Dinshaw KA
    Breast; 2008 Jun; 17(3):263-9. PubMed ID: 18060781
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic value of DNA cytometry in 281 premenopausal patients with lymph node negative breast carcinoma randomized in a control trial: multivariate analysis with Ki-67 index, mitotic count, and microvessel density.
    Mandard AM; Denoux Y; Herlin P; Duigou F; van De Vijver MJ; Clahsen PC; van Den Broek L; Sahmoud TM; Henry-Amar M; van De Velde CJ
    Cancer; 2000 Oct; 89(8):1748-57. PubMed ID: 11042570
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cyclin E1 is a strong prognostic marker for death from lymph node negative breast cancer. A population-based case-control study.
    Lundgren C; Ahlin C; Holmberg L; Amini RM; Fjällskog ML; Blomqvist C
    Acta Oncol; 2015 Apr; 54(4):538-44. PubMed ID: 25327158
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclin B is an immunohistochemical proliferation marker which can predict for breast cancer death in low-risk node negative breast cancer.
    Koliadi A; Nilsson C; Holmqvist M; Holmberg L; de La Torre M; Wärnberg F; Fjällskog ML
    Acta Oncol; 2010 Aug; 49(6):816-20. PubMed ID: 20307242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormone receptors and proliferation in breast carcinomas of equivalent histologic grades in pre- and postmenopausal women.
    Talley LI; Grizzle WE; Waterbor JW; Brown D; Weiss H; Frost AR
    Int J Cancer; 2002 Mar; 98(1):118-27. PubMed ID: 11857395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment results and prognostic factors of early breast cancer treated with a breast conserving operation and radiotherapy.
    Kim KJ; Huh SJ; Yang JH; Park W; Nam SJ; Kim JH; Lee JH; Kang SS; Lee JE; Kang MK; Park YJ; Nam HR
    Jpn J Clin Oncol; 2005 Mar; 35(3):126-33. PubMed ID: 15741302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of subcutaneous mastectomy with radical mastectomy.
    Horiguchi J; Iino JHY ; Takei H; Koibuchi Y; Iijima K; Ikeda F; Ochiai R; Uchida K; Yoshida M; Yokoe T; Morishita Y
    Anticancer Res; 2001; 21(4B):2963-7. PubMed ID: 11712794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The prognostic value of Ki67 in systemically untreated patients with node-negative breast cancer.
    Pathmanathan N; Balleine RL; Jayasinghe UW; Bilinski KL; Provan PJ; Byth K; Bilous AM; Salisbury EL; Boyages J
    J Clin Pathol; 2014 Mar; 67(3):222-8. PubMed ID: 24403187
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Breast-conservation treatment for early invasive breast cancer: prognostic factors for survival after salvage treatment of local recurrence].
    Fodor J
    Magy Onkol; 2007; 51(2):127-31. PubMed ID: 17660868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cyclin E and survival in patients with breast cancer.
    Keyomarsi K; Tucker SL; Buchholz TA; Callister M; Ding Y; Hortobagyi GN; Bedrosian I; Knickerbocker C; Toyofuku W; Lowe M; Herliczek TW; Bacus SS
    N Engl J Med; 2002 Nov; 347(20):1566-75. PubMed ID: 12432043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic value of breast cancer subtypes on breast cancer specific survival, distant metastases and local relapse rates in conservatively managed early stage breast cancer: a retrospective clinical study.
    Sanpaolo P; Barbieri V; Genovesi D
    Eur J Surg Oncol; 2011 Oct; 37(10):876-82. PubMed ID: 21824742
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Which cyclin E prevails as prognostic marker for breast cancer? Results from a retrospective study involving 635 lymph node-negative breast cancer patients.
    Sieuwerts AM; Look MP; Meijer-van Gelder ME; Timmermans M; Trapman AM; Garcia RR; Arnold M; Goedheer AJ; de Weerd V; Portengen H; Klijn JG; Foekens JA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3319-28. PubMed ID: 16740753
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Positive sentinel node risk in relation to oestrogen receptors in breast cancer in premenopausal and postmenopausal women].
    Bajén MT; Benítez AM; Domènech A; Ricart Y; Mora J; Notta P; Ramal D; Urruticoechea A; Soler T; Martín-Comin J
    Rev Esp Med Nucl; 2010; 29(6):289-92. PubMed ID: 20828880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.